Last updated on August 2020

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Brief description of study

The primary objective of this trial is to determine the maximum tolerated dose (MTD) of BI 905677 given as an intravenous infusion and to determine the recommended dose and dosing schedule for further trials in the development of BI 905677. The MTD will be defined based on the frequency of patients experiencing Dose Limiting Toxicity (DLT)s during the MTD evaluation period, which is defined as the first cycle of treatment. Separate MTDs will be determined for dosing Schedule A and dosing Schedule B. Recruitment into Schedule B will start after the MTD of Schedule A is reached.

The secondary objective of the trial is:

  • To determine the pharmacokinetic profile of BI 905677

Clinical Study Identifier: NCT03604445

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.